Based on ratings from 4 stock analysts, the Omnicell Inc stock price is expected to increase by 18.96% in 12 months. This is calculated by using the average 12-month stock price forecast for Omnicell Inc. The lowest target is $26.00 and the highest is $39.00. Please note analyst price targets are not guaranteed and could be missed completely.
OMCL is a stock in Technology which has been forecasted to be worth $34.00 as an average. On the higher end, the forecast price is $39.00 USD by jessica tassan from Piper Sandler and on the lower end OMCL is forecasted to be $26.00 by stan berenshteyn from Wells Fargo.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
bill sutherland Benchmark Co. | Buy | $38.0 | maintained | Feb 9, 2024 |
stan berenshteyn Wells Fargo | Hold | $26.0 | maintained | Feb 9, 2024 |
allen lutz Bank of America Securities | Buy | $38.0 | reiterated | Feb 8, 2024 |
stephanie davis Barclays | Sell | $33.0 | initiatedcoverage | Jan 2, 2024 |
jessica tassan Piper Sandler | Buy | $39.0 | rated | Nov 29, 2023 |
anne samuel J.P. Morgan | Hold | $28.0 | maintained | Nov 6, 2023 |
matt hewitt Craig-Hallum | Buy | $50.0 | maintained | Nov 3, 2023 |
scott schoenhaus KeyBanc | Hold | None | reiterated | Nov 3, 2023 |
david larsen BTIG | Hold | None | downgraded | Nov 2, 2023 |
whit mayo SVB Securities | Hold | $58.0 | rated | Mar 29, 2023 |
sean wieland Piper Sandler | Buy | $66.0 | maintained | Feb 22, 2023 |
joy zhang cfa SVB Securities | Hold | $54.0 | reiterated | Dec 15, 2022 |
dev weerasuriya Berenberg Bank | Buy | $73.0 | maintained | Dec 14, 2022 |
iris long Berenberg Bank | Hold | None | rated | Dec 13, 2021 |
steven halper Cantor Fitzgerald | Hold | $155.0 | maintained | Nov 2, 2021 |
eugene mannheimer Colliers Securities | Buy | $164.0 | reiterated | Jul 29, 2021 |
jamie stockton Wells Fargo | Hold | $84.0 | maintained | Oct 28, 2020 |
mitra ramgopal Sidoti | Hold | $82.0 | maintained | Oct 25, 2019 |
charles rhyee Cowen & Co. | Hold | $29.0 | maintained | Oct 30, 2015 |
steven crowley Craig-Hallum | Hold | None | downgraded | Nov 1, 2013 |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.
When did it IPO
2001
Staff Count
3,890
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Randall A. Lipps
Market Cap
$1.30B
In 2023, OMCL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that OMCL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
AKRO-USD
$24.21
FWRD-USD
$39.67
OLPX-USD
$2.14
EXTR-USD
$11.83
$5.74
NTCT-USD
$22.26